6 results
Primary:• To demonstrate the therapeutic equivalence of ONS-3010 (adalimumab biosimilar) compared toHumira® (adalimumab) in patients with plaque psoriasis Secondary:• To assess the safety, tolerability, and immunogenicity of ONS-3010 compared to…
The primary objective is to investigate and compare the pharmacokinetic (PK) of MSB11022 acetate versus MSB11022-citrate in healthy subjects.
PrimaryThe primary objective is to compare both ixekizumab regimens (80 mg every 2 weeks [Q2W] or 80 mg every 4 weeks [Q4W]) versus placebo in patients with active radiographic axial spondyloarthritis (rad-axSpA) at Week 16.SecondaryThe major…
The purpose of this study is to compare the safety and efficacy of secukinumab monotherapy and adalimumab monotherapy in patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy for PsA or PsO and are intolerant or having…
Primary objective:Assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe HS who are surgical candidates.Secondary objectives:Assess the impact of adalimumab on the planned HS surgical site before surgery,…
To assess non-inferiority of extending the adalimumab dosing interval, under strict disease monitoring in CD patients in sustained (>9months) clinical remission, compared to standard care.